** Shares of drug developer Arrowhead Pharmaceuticals ARWR.O fall 11.6% to $14.91
** Bernstein analyst William Pickering says ARWR's price action reflects "increasing investor concern on partner Sarepta's SRPT.O ability to pay Arrowhead $300 million in near-term milestones" due under their 2024 partnership
** Last year, Arrowhead signed a license and collaboration agreement with Sarepta for multiple clinical and preclinical programs
** Sarepta Therapeutics' shares down 4% at $13.49
** The concerns stem from recent deaths of patients treated with Sarepta gene therapies including Elevidys; company has also refused to comply with FDA's request on Friday to halt shipments of Elevidys
** B. Riley Securities analyst Madison El-Saadi says "SRPT-partnered neuromuscular candidates are high-value and are of investor interest"
** El-Saadi calls ARWR's partnered drug programs "a lifeline" for SRPT
** Pickering also notes that "Arrowhead stock has a history of very large swings on news perceived to impact its cash position and liquidity"
** Including session's moves, ARWR down 21% YTD and SRPT down 90%
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。